z-logo
Premium
Paravalvular regurgitation one year after transcatheter aortic valve implantation
Author(s) -
Rajani Ronak,
Kakad Mitesh,
Khawaja Muhammed Z.,
Lee Lorraine,
James Rachael,
Saha Mrinal,
HildickSmith David
Publication year - 2010
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.22399
Subject(s) - medicine , regurgitation (circulation) , incidence (geometry) , cardiology , aortic valve regurgitation , surgery , physics , optics
Objectives : The aim of this study was to assess the natural history of paravalvular regurgitation at 1 year in patients undergoing TAVI. Background : The immediate incidence of paravalvular regurgitation is estimated to be between 65 and 85% following transcatheter aortic valve implantation (TAVI). There is limited data as to whether this deteriorates during follow‐up. Methods : Forty‐six patients were recruited from a TAVI programme at our institute. All patients underwent an assessment of prosthetic valve function periprocedurally with aortography and immediately postprocedurally with transthoracic echocardiography. Twenty‐one patients with a median age was 83 (66–91) years of whom 14 were male reached 1 year follow‐up, 13 of whom were available for repeat transthoracic echocardiography. Results : The incidence of paravalvular regurgitation immediately following TAVI was 86%. Of them 57% had ≤ mild regurgitation and 29% had > mild regurgitation. At 1 year the incidence of paravalvular regurgitation was 77%. 54% had ≤ mild regurgitation and 34% > mild regurgitation. No patient had severe regurgitation. The degree of regurgitation reduced in 6 (46%), stayed the same in 3 (23%), and increased in 4 (31%) of patients. Conclusions : Patients undergoing TAVI have an immediate postprocedural risk of regurgitation of 86%. In the majority of cases the degree of paravalvular CoreValve® regurgitation is mild, and remains stable in 70% of patients during medium term follow‐up. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom